CD137

From Wikipedia, the free encyclopedia
Jump to: navigation, search
TNFRSF9
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases TNFRSF9, 4-1BB, CD137, CDw137, ILA, tumor necrosis factor receptor superfamily member 9, TNF receptor superfamily member 9
External IDs OMIM: 602250 MGI: 1101059 HomoloGene: 1199 GeneCards: TNFRSF9
Gene location (Human)
Chromosome 1 (human)
Chr. Chromosome 1 (human)[1]
Chromosome 1 (human)
Genomic location for TNFRSF9
Genomic location for TNFRSF9
Band 1p36.23 Start 7,915,894 bp[1]
End 7,943,165 bp[1]
RNA expression pattern
PBB GE TNFRSF9 211786 at fs.png

PBB GE TNFRSF9 207536 s at fs.png
More reference expression data
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001561

NM_001077508
NM_001077509
NM_011612

RefSeq (protein)

NP_001552

NP_001070976
NP_001070977
NP_035742

Location (UCSC) Chr 1: 7.92 – 7.94 Mb Chr 1: 150.91 – 150.95 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

CD137 is a member of the tumor necrosis factor (TNF) receptor family. Its alternative names are tumor necrosis factor receptor superfamily member 9 (TNFRSF9), 4-1BB and induced by lymphocyte activation (ILA). It is currently of interest to immunologists as a co-stimulatory immune checkpoint molecule.

Expression[edit]

CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, B cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation.

Specific effects on cells[edit]

The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion, survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice.

Interactions[edit]

CD137 has been shown to interact with TRAF2.[5][6]

As a drug target[edit]

Utomilumab[edit]

Utomilumab (PF-05082566) targets this receptor to stimulate a more intense immune system attack on cancers.[7] It is a fully human IgG2 monoclonal antibody.[8] It is in early clinical trials.[7] As of June 2016 5 clinical trials are active.[9]

See also[edit]

References[edit]

External links[edit]

Further reading[edit]